drugset / Trial / NCT02315157
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of bendamustine hydrochloride in treating patients with previously treated multiple myeloma. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2014-06
- Primary completion
- 2018-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Bendamustine | Small molecule | 250 mg/m2 | Intravenous |